Comment · Fri, April 26, 2013 · Ceretropic
IDRA-21 Super racetam/nootropic
Original post in this thread
redan-yadayada · 17 points
Hey guys. I'm a regular at Longecity and recently found this place. We're conducting a couple of group buys at Longecity for interesting compounds. One compound that's caught my eye is "IDRA-21." Of all the racetams and AMPA'kines this one looks really promising. There has been some concerns over its potency and duration of activity; but, I believe these can be mitigated with the proper dosing and co-administration of other neuroprotective compounds. I am looking for responsible individuals to participate in a potential group buy of this compound. Please, post your interest here and we can start a group buy over at Longecity. Anyway, thanks.
What they were answering
Direct reply to the original post — see the thread post above.
u/MisterYouAreSoDumb · Ceretropic
Hey yadayada, I was the one speaking to you yesterday on Longecity. Glad you decided to make an account here.
I got this paper from 2004 that shows it could be a very promising AMPAkine. It was performed on rhesus monkeys.
> For three subjects Best Dose was 0.3 mg/kg; for two subjects Best Dose was 0.15 mg/kg; for one animal Best Dose was 3
mg/kg; and for one animal Best Dose was 10 mg/kg. Again this pattern fits with the complex nature of the
dose-response relationship. The average Best Dose for the study group was 1.9 ± 1.6 mg/kg. Examination of
Fig. 3 reveals a pattern of strong improvements in task accuracy.
So it looks like the dose/response relationship is fairly variable.
>IDRA 21 effectively increased task accuracies in our
young monkeys with a sustained level of improvement
that was apparent for at least 48 hr after drug administration. This was at first surprising in view of the short
(less than 1 hr) plasma half-life (Yamada, 1998).
So it looks like the effects last 48 hours from a single dose, even though the half life is much shorter. Very interesting!
>There were other age-related differences apparent in
the study. The overall degree of effectiveness of IDRA
21 in the older group was not quite as robust as it was
in young animals, and aged subjects also appeared to be
more individually sensitive to drug dose. We attempted
to relate the assigned Long delay interval to the drug
response associated the individual Best Dose (Fig. 7).
For the young animals a significant relationship was
obtained between the duration of the assigned Long
delay interval and the increase in accuracy associated
with the Best Dose. This relationship was not apparent
for the aged cohort. In fact, this analysis serves to sup-
port the possibility that IDRA 21 is more effective in
young or non-baseline-impaired animals than it is in
aged-impaired animals.
It also seems that it is more effective in young healthy individuals rather than older or impaired individuals. It could be a damn good nootropic!
Have you already found a lab to do the synth?